Health Canada has approved TALTZ (ixekizumab) for the Treatment of Active Ankylosing Spondylitis (Radiographic Axial Spondyloarthritis)
[caption id="attachment_9277" align="aligncenter" width="747"] Press Release[/caption]
- COAST-V: 48% of patients treated with TALTZ every four weeks versus 18% of patients treated with placebo (p<0.001)
- COAST-W: 25% of patients treated with TALTZ every four weeks versus 13% of patients treated with placebo (p<0.05)
- COAST-V: 64% of patients treated with TALTZ every four weeks versus 40% of patients treated with placebo (p<0.01)
- COAST-W: 48% of patients treated with TALTZ every four weeks versus 30% of patients treated with placebo (p<0.01)
Media Contact: Samira Rehman Rehman_Samira@lilly.com 647-617-1994
REFERENCES 1?Arthritis Society. https://arthritis.ca/about-arthritis/arthritis-types-(a-z)/types/ankylosing-spondylitis 2?TALTZ Product Monograph.